Not found

Jianguo Wen, PhD

Assistant Research Professor of Pathology and Genomic Medicine, Institute for Academic Medicine
Assistant Research Member, Research Institute
Houston Methodist


Dr. Jianguo Wen earned his Ph.D. in Genetics from Fudan University in 2004. He joined Houston Methodist Research Institute in 2005 and completed his postdoctoral training in the Department of Pathology.

Description of Research

Dr. Wen’s research program focuses on pathogenesis and preclinical treatment of multiple myeloma. Current research efforts aim to develop therapies targeting multiple myeloma cancer stem cells.

Areas Of Expertise

Cancer Stem cells Multiple myeloma
Education & Training

PhD , Fudan University
Postdoctoral Fellowship , Houston Methodist Research Institute
MS , Northwest Sci-Tec University of Agriculture and Forestry, Shaanxi

Aptamer internalization via endocytosis inducing s-phase arrest and priming maver-1 lymphoma cells for cytarabine chemotherapy
Li, H, Yang, S, Yu, G, Shen, L, Fan, J, Xu, L, Zhang, H, Zhao, N, Zeng, Z, Hu, T, Wen, J & Zu, Y 2017, Theranostics, vol 7, no. 5, pp. 1204-1213. DOI:

SsDNA aptamer specifically targets and selectively delivers cytotoxic drug doxorubicin to HepG2 Cells
Yu, G, Li, H, Yang, S, Wen, J, Niu, J & Zu, Y 2016, PLoS ONE, vol 11, no. 1, e0147674. DOI:

A unique aptamer-drug conjugate for targeted therapy of multiple myeloma
Wen, J, Tao, W, Hao, S, Iyer, SP & Zu, Y 2016, Leukemia, vol 30, no. 4, pp. 987-91. DOI:

Utilizing a high-throughput microfluidic platform to study hypoxia-driven mesenchymal-mode cell migration
Zhang, Y, Wen, J, Zhou, L & Qin, L 2015, Integrative Biology (United Kingdom), vol 7, no. 6, pp. 672-680. DOI:

Mutated genes and driver pathways involved in myelodysplastic syndromes - a transcriptome sequencing based approach
Liu, L, Wang, H, Wen, J, Tseng, CE, Zu, Y, Chang, CC & Zhou, X 2015, Molecular BioSystems, vol 11, no. 8, pp. 2158-2166. DOI:

Dynamic balance of multiple myeloma clonogenic side population cell percentages controlled by environmental conditions
Wen, J, Tao, W, Kuiatse, I, Lin, P, Feng, Y, Jones, RJ, Orlowski, RZ & Zu, Y 2015, International Journal of Cancer, vol 136, no. 5, pp. 991-1002. DOI:

SDF-1a stiffens myeloma Bone marrow mesenchymal stromal cells through the activation of RhoA-ROCK-Myosin II
Choi, DS, Stark, DJ, Raphael, RM, Wen, J, Su, J, Zhou, X, Chang, CC & Zu, Y 2015, International Journal of Cancer, vol 136, no. 5, pp. E219-E229. DOI:

Characterization of p38 MAPK isoforms for drug resistance study using systems biology approach
Peng, H, Peng, T, Wen, J, Engler, DA, Matsunami, RK, Su, J, Zhang, L, Chang, CC & Zhou, X 2014, Bioinformatics, vol 30, no. 13, pp. 1899-1907. DOI:

Targeting the biophysical properties of the myeloma initiating cell niches: A pharmaceutical synergism analysis using multi-scale agent-based modeling
Su, J, Zhang, L, Zhang, W, Choi, DS, Wen, J, Jiang, B, Chang, CC & Zhou, X 2014, PLoS ONE, vol 9, no. 1, e85059. DOI:

High throughput quantitative reverse transcription PCR assays revealing over-expression of cancer testis antigen genes in multiple myeloma stem cell-like side population cells
Wen, J, Li, H, Tao, W, Savoldo, B, Foglesong, JA, King, LC, Zu, Y & Chang, CC 2014, British Journal of Haematology, vol 166, no. 5, pp. 711-719. DOI:

Discovering transcription and splicing networks in myelodysplastic syndromes
Wang, H, Wen, J, Chang, CC & Zhou, X 2013, PLoS ONE, vol 8, no. 11, e79118. DOI:

Biostable ssDNA aptamers specific for Hodgkin lymphoma.
Parekh, P, Kamble, S, Zhao, N, Zeng, Z, Wen, J, Yuan, B & Zu, Y 2013, Sensors (Basel, Switzerland), vol 13, no. 11, pp. 14543-14557. DOI:

Cancer stem cells: A review of potential clinical applications
Podberezin, M, Wen, J & Chang, CC 2013, Archives of Pathology and Laboratory Medicine, vol 137, no. 8, pp. 1111-1116. DOI:

Research article: Monitoring the progression of metastatic breast cancer on nanoporous silica chips
Fan, J, Deng, X, Gallagher, JW, Huang, H, Huang, Y, Wen, J, Ferrari, M, Shen, H & Hu, Y 2012, Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences, vol 370, no. 1967, pp. 2433-2447. DOI:

Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: The role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system
McGowan, P, Nelles, N, Wimmer, J, Williams, D, Wen, J, Li, M, Ewton, A, Curry, C, Zu, Y, Sheehan, A & Chang, CC 2012, American Journal of Clinical Pathology, vol 137, no. 4, pp. 665-670. DOI:

A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes
Peng, H, Wen, J, Zhang, L, Li, H, Chang, CC, Zu, Y & Zhou, X 2012, Molecular BioSystems, vol 8, no. 4, pp. 1366-1374. DOI:

Selective gene transfection of individual cells in vitro with plasmonic nanobubbles
Lukianova-Hleb, EY, Samaniego, AP, Wen, J, Metelitsa, LS, Chang, CC & Lapotko, DO 2011, Journal of Controlled Release, vol 152, no. 2, pp. 286-293. DOI:

NSMAP: A method for spliced isoforms identification and quantification from RNA-Seq
Xia, Z, Wen, J, Chang, CC & Zhou, X 2011, BMC Bioinformatics, vol 12, 162. DOI:

Drug inhibition profile prediction for NF?B pathway in multiple myeloma
Peng, H, Wen, J, Li, H, Chang, J & Zhou, X 2011, PLoS ONE, vol 6, no. 3, e14750. DOI:

Integrative analysis of next generation sequencing for small non-coding RNAs and transcriptional regulation in Myelodysplastic Syndromes
Beck, D, Ayers, S, Wen, J, Brandl, MB, Pham, TD, Webb, P, Chang, CC & Zhou, X 2011, BMC Medical Genomics, vol 4, 19. DOI: